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Introduction {#sec001}
============

Hibernation is a phenomenon affected by external stimuli such as cold season, short day length and food paucity, and internal factors such as biochemical regulations and circadian rhythm. Hibernating mammals have evolved with various types of physiological and behavioral responses, which enable them to go through harsh environmental conditions. Bears, in terms of body mass, are by far the largest hibernating mammalian species. Another distinctive feature is that bears do not intake food, urinate, nor defecate during hibernation. Interestingly, hibernating bears' musculoskeletal system is not compromised by environmental and metabolic alterations throughout the torpor period \[[@pone.0238132.ref001]--[@pone.0238132.ref003]\].

Previous studies by the use of biochemical, histological, and imaging tests have clearly shown that bears do not suffer from osteoporosis despite long-term inactivity, lack of food intake and cold exposure during hibernation \[[@pone.0238132.ref004]--[@pone.0238132.ref010]\]. Similar conditions in humans and other mammals lead to osteopenia and osteoporosis, e.g. long-term inactivity and disuse such as long-term bed bound, and microgravity increase bone resorption to a rate higher than bone formation \[[@pone.0238132.ref011]--[@pone.0238132.ref015]\]. The imbalance in bone remodeling culminates in various degrees of bone loss.

There is growing evidence that the serum component can reflect the state of osteoporosis, and physical activity in humans \[[@pone.0238132.ref016]--[@pone.0238132.ref020]\]. The use of osteoporotic patients' serum in osteogenic cell culture can induce osteoporotic-like conditions *in-vitro*, such as increase in the expression of receptor activator of nuclear factor kappa-β ligand (RANKL) \[[@pone.0238132.ref021]\], a potent inducer of osteoclast (OC) differentiation, and decrease in the expression of osteogenic genes \[[@pone.0238132.ref022]\].

The use of bear serum for cell culture has been investigated in recent years. The *in-vitro* experiments have indicated that the use of active and hibernating bear serum for cell culture can induce active-like and hibernation-like cell responses, respectively \[[@pone.0238132.ref023]--[@pone.0238132.ref025]\]. For example, the use of hibernating bear serum inhibits proteolysis, and increases protein content in muscle cells \[[@pone.0238132.ref025]\].

As mentioned above, it is almost unequivocal that bears do not develop osteoporosis due to hibernation. However, the mechanisms and features that enable bears to stay safe from bone loss have largely remained unknown. Here, we present *in vitro* evidence that serum of hibernating bears suppresses osteoclastogenesis of bear peripheral blood mononuclear cells (PBMCs). PBMCs, akin to bone marrow monocytes, are considered as progenitor cells for osteoclasts. Also, here for the first time we report the formation of bear OCs *in-vitro*.

Materials and methods {#sec002}
=====================

Sampling from animals {#sec003}
---------------------

We used captive adult Japanese black bears (*Ursus thibetanus japonicus*) at Ani Mataginosato Bear Park (Kuma Kuma) located in Akita Prefecture, Japan (N 39.915398 E140.536294), in active and hibernation periods. Bear information and sample types are presented in [Table 1](#pone.0238132.t001){ref-type="table"}. The bears are routinely fed by crushed corn, acorn, chestnut, and a kind of local Japanese butterbur. During hibernation period, the bears do not have access to food, while they have access to water ad libitum. Bears hibernation was characterized by lack of movement and food intake. Hibernation in these captive bears reportedly begins in December and proceeds to around early April, when bears resume activity and foraging \[[@pone.0238132.ref026],[@pone.0238132.ref027]\]. All procedures and animal care were conducted in accordance with the Guideline of the Animal Care and Use of Hokkaido University and were approved by the Animal Care and Use Committee of Hokkaido University (Permit Number: 18--0179). To collect samples, bears were anesthetized with 40 μg/kg medetomidine hydrochloride (Domitor; Zenoaq, Fukushima, Japan) and 3.0 mg/kg zolazepam hydrochloride and tiletamine hydrochloride cocktail (Zoletil; Virbac, Carros, France) intra-muscularly. Blood was collected from the jugular vein into plain tubes, and EDTA containing tubes for serum collection and peripheral blood mononuclear cells (PBMCs) isolation, respectively. Serum was isolated from plain tubes and preserved at -80°C. EDTA containing tubes were delivered at 4°C to the lab for PBMCs isolation, as explained below. Adipose tissue was biopsied from the subcutaneous inguinal and sternal areas, put in Dulbecco's Modified Eagle's Medium (DMEM, FUJIFILM Wako Pure Chemical Corporation, Japan), and delivered at room temperature to the lab for adipose derived mesenchymal stems cells (ADSCs) isolation, as explained below.
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###### Bear information, sample type, and collection season.

![](pone.0238132.t001){#pone.0238132.t001g}

  Bears ID                                              A    B      C     K     D       E     F     G    C       D     H       I
  ----------------------------------------------------- ---- ------ ----- ----- ------- ----- ----- ---- ------- ----- ------- -----
  Age (year)                                            7    7      19    23    18      12    26    16   19      18    18      17
  Body mass[\*](#t001fn002){ref-type="table-fn"} (kg)   86   90.5   143   157   145.5   153   107   78   157.5   166   135.5   201

All samples were collected from male bears, except bear G, a female bear. May and July samples are for active phase. January samples are for hibernation phase. The average of active and hibernating bears' age (for serum samples) is 18.00 ± 2.94 and 18.00 ± 0.40, respectively. The difference between the groups' age is not significant; *p*-value = 1.00. Data were assessed by two-tailed Student\'s *t*-test.

\*Body mass at sampling season.

PBMCs isolation {#sec004}
---------------

The blood samples were obtained from 3 adult male bears A, B, and C in active season (May- July). In the lab, the blood (collected in EDTA containing tubes) collected from each bear was separately diluted with phosphate-buffered saline (PBS) to the ratio 50:50. Blood-PBS mixture was slowly added onto Ficoll-Paque PLUS (GE Healthcare Life Sciences, Sweden) in falcon tubes based on the instruction of the product. The tubes were centrifuged at 400 × g, for 40 minutes at 20°C. The buffy coat was collected and transferred to new falcon tubes, and were centrifuged twice with PBS at 400 × g for 15 and 10 minutes at 20°C. Finally, the PBMCs from each bear were separately collected in Eppendorf tubes, and preserved in CELLBANKER 2 (AMS Biotechnology Ltd., UK) at -80°C.

ADSCs isolation {#sec005}
---------------

Adipose tissue was obtained from a mature male black bear (bear K) in active season. The tissues were digested by 2 mg/ml collagenase (FUJIFILM Wako Pure Chemical Corporation, Japan) in DMEM containing 2% fatty acid-free bovine serum albumin (BSA) (FUJIFILM Wako Pure Chemical Corporation) at 37 ºC for 2 h with shaking at 90 cycles/min. The suspension was filtered through 200-μm nylon filter and centrifuged at 200 × g for 5 min at room temperature. The pellet was filtered through 25-μm nylon filter, and then centrifuged at 200 × g for 5 min at room temperature. The pellet was collected as ADSCs, and preserved in CELLBANKER 2 (AMS Biotechnology Ltd., UK) (Takara Bio Inc., Japan) at -80°C. This method is based on our previously established protocol for ADSCs isolation from adipose tissue \[[@pone.0238132.ref028]\].

Cell culture {#sec006}
------------

PBMCs were cultured at a concentration of 3 to 5 × 10^6^ cells per 35 mm collagen-coated dish, in a-MEM (Minimum Essential Medium Eagle, Sigma-Aldrich, UK.) supplemented with10% bear serum, 100 units/ml penicillin-streptomycin (FUJIFILM Wako Pure Chemical Corporation), 50 μg/ml gentamicin (FUJIFILM Wako Pure Chemical Corporation), 2.5 μg/ml amphotericin B (FUJIFILM Wako Pure Chemical Corporation) and 2 mM L-Glutamine (Nacalai Tesque Inc., Japan), and incubated at 37°C with 5% CO~2~. Protocol for the OC differentiation is summarized in [Fig 1](#pone.0238132.g001){ref-type="fig"}. The day after seeding (day 2), the supernatant was discarded, and cells either *i*) at a concentration of 0.2 to 0.5 × 10^5^ cells per well were seeded on 96-well plate or *ii*) at the same dish remained to the end of experiment, were cultured with the same medium/serum type with addition of 20 ng/ml macrophage colony stimulating factor (M-CSF, Gibco, USA.) for three days. On day 5 and 8, the medium was changed to new medium containing 20 ng/ml M-CSF and 50 ng/ml RANKL (Sigma-Aldrich, USA.). On day 11, cells were finally washed with PBS, fixed with 10% phosphate-buffered formalin, washed with distilled water, and stained with TRAP Stain (TRAP staining kit, Cosmobio Co., LTD., Japan) to examine the presence of tartrate-resistant acid phosphatase (TRAP) by a light microscope. The stained area in each dish was quantified by the use of NIH Image J Software.

![The procedure of PBMCs culture from day 1 to 11 to form OCs.](pone.0238132.g001){#pone.0238132.g001}

PBMCs of bears A, B, and C were separately cultured with active bear serum containing medium (ABSM) prepared separately from serum of bears D, E, F, and G, and hibernating bear serum containing medium (HBSM) prepared separately from serum of bears C, D, H, and I ([Table 1](#pone.0238132.t001){ref-type="table"}). PBMCs of bear A and B were twice evaluated for the mentioned procedure on dish and plate. All groups were treated with MCSF and RANKL equally and similarly.

ADSCs from one bear (bear K) were cultured on 35 mm collagen-coated dish (cell concentration shown in the results) with 10% ABSM or 10% HBSM, each from 4 different individuals, as mentioned for PBMCs. ADSCs were twice cultured; after 6 days (medium changed at day 3), cells were detached by trypsin/EDTA solution, counted on hemocytometer, re-cultured (subculture), and after 4 days, detached and recounted. At each passage, ADSCs were cultured separately with each of four types of ABSM and HBMS.

Statistical analysis {#sec007}
--------------------

Values are expressed as mean ± standard error (SE). The data were analyzed by the use of analysis of two-tailed Student's *t*-test or Analysis of Variance (ANOVA) together with a post-hoc Tukey HSD (by the use of IBM SPSS Statistics, Version 23), and significant *p*-value was considered equal or less than 0.05.

Results {#sec008}
=======

PBMCs culture and TRAP staining {#sec009}
-------------------------------

PBMCs from bears A, B, and C ([Table 1](#pone.0238132.t001){ref-type="table"}) were cultured with either ABSM or HBSM, and induced differentiation to OCs by treatment with M-CSF and RANKL ([Fig 1](#pone.0238132.g001){ref-type="fig"}). On day11, PBMCs cultured with ABSM showed multi-nucleated morphology, a typical feature of OCs. These multi-nucleated cells were positively stained for TRAP activity, indicating differentiation to active OCs ([Fig 2A and 2B](#pone.0238132.g002){ref-type="fig"}). By contrast, PBMCs cultured with HBSM failed to differentiate to multi-nucleated cells (Figs [1C](#pone.0238132.g001){ref-type="fig"} and [2D](#pone.0238132.g002){ref-type="fig"}). TRAP-stained area in ABSM group was 21.28 ± 3.89% of total area, being significantly (*p*-value \< 0.001) higher than that in HBSM group (1.73 ± 0.43%) ([Fig 3](#pone.0238132.g003){ref-type="fig"}).

![TRAP stained samples at day 11.\
(A-B) cultured cells of bears B and C with active bear serum containing medium (ABSM); multi-nucleated giant osteoclasts which are TRAP stain positive. (C-D) cultured cells of bears B and C with hibernating bear serum containing medium (HBSM); non-differentiated cells, which are poorly stained with TRAP stain. Scale bar is equal to 500 μm.](pone.0238132.g002){#pone.0238132.g002}

![The percentage of TRAP stained areas in osteoclast cultures.\
Bear A cultured with active bear serum containing medium (ABSM) (n = 4), and hibernating bear serum containing medium (HBSM) (n = 4). \* *p*-value = 0.040. Bear B cultured with ABSM (n = 4), and HBSM (n = 4). \* *p*-value = 0.028. Bear C cultured with ABSM (n = 3), and HBSM (n = 3). *p*-value, = 0.242. Total of three bears: ABSM (n = 11), and HBSM (n = 11). \* *p*-value = 0.0005. Data were assessed by two-tailed Student's *t*-test. All values represent means ± SE.](pone.0238132.g003){#pone.0238132.g003}

ADSCs culture and cell number count {#sec010}
-----------------------------------

ADSCs were cultured with either ABSM or HBSM and effect on cell proliferation was examined. At the first passage, 6-day culture showed significant (*p*-value \< 0.05) increase in cell number ([Fig 4A](#pone.0238132.g004){ref-type="fig"}) and the growth rate showed no significant difference between ADSCs cultured with ABSM (2.7-fold) and HBSM (2.9-fold) ([Fig 4A](#pone.0238132.g004){ref-type="fig"}). At the second passage, cell number significantly (*p*-value \< 0.05) increased in both ABSM and HBSM ([Fig 4B](#pone.0238132.g004){ref-type="fig"}). Growth rates of ABSM and HBSM groups were similar in 4-day culture at the second passage ([Fig 4B](#pone.0238132.g004){ref-type="fig"}). ADSCs in both groups turned to spindle-shaped cells at day 6 (first culture), and day 4 (subculture/ second culture) ([Fig 5](#pone.0238132.g005){ref-type="fig"}).

![The cell number of Adipose Derived Stem Cells (ADSCs) of bear K cultured with active bear serum (separately with each serum of bear D, E, F, and G) containing medium (ABSM) and hibernating bear serum (separately with each serum of bear C, D, H, I) containing medium (HBSM) for the first and second passage.\
(A) First passage; there was a significant difference between groups as determined by one-way ANOVA (F(3--12) = 21.80, *p*-value \<0.001). Post-hoc comparisons using Tukey HSD test indicated that there was a significant difference between day 1 and 6 in ABSM group *p*-value = 0.001 and in HBSM group \* *p*-value \< 0.001. The difference between ABSM and HBSM at day 6 was not significant (N.S); *p*-value = 0.914. (B) Second passage; there was a significant difference between groups as determined by one-way ANOVA (F(3--12) = 18.59, *p*-value \<0.001). Post-hoc comparisons using Tukey HSD test indicated that there was a significant difference between day 1 and 4 in ABSM group \* *p*-value = 0.007, and in HBSM group \* *p*-value \< 0.001. The difference between ABSM and HBSM at day 4 was not significant (N.S); *p*-value = 0.224. Each column shows the average of total cell numbers of 4 separate cultures based on 4 types of ABSM and 4 types of HBSM. All values represent means ± SE.](pone.0238132.g004){#pone.0238132.g004}

![Second passage of Adipose Derived Stem Cells (ADSCs) cultured with active bear serum containing medium (ABSM) and hibernating bear serum containing medium (HBSM) in time intervals: 3 hours, day 2 and day 4 post seeding.\
This indicates a similar trend in cell growth for both ABSM and HBMS. Scale bar is equal to 500 μm. Arrows show 100% zoomed areas in the square.](pone.0238132.g005){#pone.0238132.g005}

Discussion {#sec011}
==========

PBMCs and bone marrow derived monocytes/macrophages (BMM) are ubiquitously used for *in-vitro* osteoclastogenesis. Previous investigations have presented *in-vitro* OC formation from different mammalian species such as humans \[[@pone.0238132.ref029]\], primates \[[@pone.0238132.ref030]\], rodents \[[@pone.0238132.ref031]\], dogs \[[@pone.0238132.ref032]\], cats \[[@pone.0238132.ref033],[@pone.0238132.ref034]\], rabbits \[[@pone.0238132.ref035]\], horses \[[@pone.0238132.ref036]\], and pigs \[[@pone.0238132.ref037]\]. To the best of our knowledge, the current work is the first to report bears' OC formation *in-vitro*. In this study we used bears' PBMCs for OC formation *in-vitro*. In order to obtain PBMCs, only blood should be collected, which is a low risk, less invasive and inexpensive method in comparison with bone marrow collection method for isolation of BMM, particularly for wild animals such as bears.

In *in-vitro* culture, under the influence of M-CSF and RANKL treatment, PBMCs differentiate to macrophage/pre-OCs, which is followed by cell fusion. Mature and functional OCs are characterized by the presence of multiple nuclei in a very large unified cell (multi-nucleated giant cells) which produce TRAP (TRAP stain positive) ([Fig 2A and 2B](#pone.0238132.g002){ref-type="fig"}) \[[@pone.0238132.ref038]--[@pone.0238132.ref042]\].

Here we demonstrated that bears' PBMCs that were cultured with ABSM could differentiate to OCs and were significantly TRAP positive. However, PBMCs that were cultured with HBSM failed to differentiate to OCs, and were almost negative to TRAP staining (Figs [2](#pone.0238132.g002){ref-type="fig"} and [3](#pone.0238132.g003){ref-type="fig"}). This is consistent with a previous study demonstrating that denning (hibernating) bears' serum derived components (isolates) inhibited chicken BMM from OCs formation \[[@pone.0238132.ref043]\]. Biochemical experiments indicated that the genes which contribute to OCs formation and differentiation (such as *Ostf1*, *Rab9a*, and *c-Fos*) are underexpressed in hibernating bears \[[@pone.0238132.ref009]\]. Also, the level of serum TRAP (a bone resorption biomarker) is significantly lower in hibernation period than before and after hibernation in bears \[[@pone.0238132.ref010]\]. In addition, histological and imaging tests revealed that trabecular and compact bone mass of the front and hind limbs are not compromised in hibernating bears. The bone mass preservation has been suggested to be related to a reduced, yet balanced, bone turnover during hibernation \[[@pone.0238132.ref004],[@pone.0238132.ref005],[@pone.0238132.ref006],[@pone.0238132.ref008]\].

In the present work, we observed that HBSM group could not differentiate into OCs. Both ABSM and HBSM groups were treated similarly; the only variable was the type of serum which was either hibernation or normal type. This could, in part, made us speculate that "serum factors that modulate cell differentiation are compromised during winter dormancy due to lack of food intake". In other words, we speculated that hibernation phase serum is not "rich enough" for cell culture. Hence, in another experiment, we tested both ABSM and HBSM on bears' adipose-derived stem cell culture (ADSCs). Interestingly, treatment of a bear ADSCs with both serum types of the same 8 bears (4 ABSM and 4 HBSM) indicated significant cell growth, and formation of spindle-like mesenchymal cell (Figs [4](#pone.0238132.g004){ref-type="fig"} and [5](#pone.0238132.g005){ref-type="fig"}). We also ruled out the effect of culture dish where we used 35 mm collagen-coated dish for both PBMCs and ADSCs culture. These findings indicate that HBSM is "not poor" for ADSCs culture; however, HBSM (unlike ABSM) fails to promote PBMCs culture.

Previous investigations on bear adipocyte culture by active and hibernating bear serum represented metabolic profiles similar to *in-vivo* \[[@pone.0238132.ref024]\]. In addition, bears' ADSCs have shown optimal differentiation to different cell lineages such as chondroblasts and osteoblasts \[[@pone.0238132.ref044],[@pone.0238132.ref045]\]. Human osteoblasts that were cultured with bear serum proliferate well \[[@pone.0238132.ref046],[@pone.0238132.ref047]\]. Furthermore, the osteoblasts show similar response to hibernation and active bear serum \[[@pone.0238132.ref046],[@pone.0238132.ref047]\]. Altogether, it can be deduced that while hibernating phase serum hinders OC formation, it retains the proliferative and differentiating potential for ADSCs and osteoblasts. This may, in part, participate in hibernating bears' bone mass maintenance.

Still, it remains questionable how hibernating phase serum can hinder osteoclastogenesis, and which serum factors or mechanisms are involved in this phase. Studies on hibernating bears have denoted that there are various serum factors that play roles in bone metabolism. For instance, *i*) Parathyroid hormone (PTH) is thought to have major anabolic effects on bone metabolism in American black bears (*Ursus americanus*) \[[@pone.0238132.ref002],[@pone.0238132.ref048]\]. Gray et al. \[[@pone.0238132.ref049]\] reported that treatment of dystrophin-deficient mice with black bear's PTH decreased osteoclastic surface and increased osteoblastic surface on the bone, leading to significantly higher hind limb bone density than control group \[[@pone.0238132.ref049]\]. *ii*) It has been reported that melatonin concentration during hibernation is about 7.5 times higher than summer active phase in brown bears (*Ursus arctos*) \[[@pone.0238132.ref050]\]. Melatonin has indicated inhibitory effects on osteoclastogenesis *in-vitro*. This was partially attributed to the increased osteoprotegerin: RANKL ratio, by inhibiting RANKL expression in osteoblasts \[[@pone.0238132.ref051]--[@pone.0238132.ref053]\]. *iii*) It is also possible that serum factors affect bone metabolism indirectly through the modulation of circadian rhythm. Jansen et al., \[[@pone.0238132.ref023]\] showed when bear's fibroblasts were cultured with active and hibernation phase serum containing medium, cell molecular rhythm was akin to those of active and hibernation phases, respectively. Circadian rhythm can govern OC activity and formation through different pathways, such as: 1) Regulation of aryl hydrocarbon receptor nuclear translocator-like (Bmal1) in OC \[[@pone.0238132.ref054]\], 2) Modulation of Bmal1 in osteoblasts which leads to alteration in RANKL expression \[[@pone.0238132.ref055]\], and 3) β-adrenergic and glucocorticoid signaling in OC \[[@pone.0238132.ref056],[@pone.0238132.ref057]\]. *iv*) Black bears' serum immune related factors are altered during hibernation, some of which are thought to affect bone metabolism, e.g. α2-HS-glycoprotein (AHSG), which is an osteogenic inhibitor, is downregulated in winter dormancy \[[@pone.0238132.ref058]\].

The present study for the first time revealed the influence of HBSM on osteoclastogenesis. There are more serum factors than stated above, which are likely to be involved in hampering OC formation/activity, and general bone metabolism \[[@pone.0238132.ref002],[@pone.0238132.ref048]\]. These demand very large-scale tests to examine the efficacy of the serum factors on OC progenitors. In our preliminary tests, we examined the heat inactivation of bear serum on PBMCs culture. These tests failed to show any differentiation in PBMCs culture either with heat-inactivated ABSM or heat-inactivated HBSM. However, when heat-inactivated ABSM and HBSM were applied to ADSCs, the cell growth was comparable with normal (unheated) ABSM and HBSM. It has been suggested that the failure in cell culture with heat inactivation of serum might be due to some cell lineages \[[@pone.0238132.ref059]\]. It is noteworthy that bone remodeling includes bone resorption and bone formation, undertaken by osteoclasts and osteoblasts, respectively. Former studies suggested that both bone formation and resorption are equally suppressed in hibernating bears; an equilibrium which sustain bone remodeling at a low rate in order to save energy for a long-term torpor \[[@pone.0238132.ref004],[@pone.0238132.ref008]--[@pone.0238132.ref010]\]. The present study shed light on OCs, indicating that bears PBMCs under the influence of HBSM fail to form OC in *in-vitro* condition. Osteoclastogenesis markers such as β3 integrin, cathepsin K, TRAP, and calcitonin are required to be explored regarding bears PBMCs differentiation in the future studies. It must be noted that, PBMCs are not the only source for OC formation *in-vivo*, i.e. bone marrow monocytes, and bone macrophages also account for osteoclastogenesis and bone resorption \[[@pone.0238132.ref060]--[@pone.0238132.ref063]\]. Therefore, the effect of HBSM on other OC progenitors remains to be explored. Moreover, further investigations are required to demonstrate biochemical alterations that regulate osteoclastogenesis during winter dormancy.

The evolutionary trends and physiological attributes that enable hibernating mammals such as bears \[[@pone.0238132.ref004],[@pone.0238132.ref005]\], ground squirrels \[[@pone.0238132.ref064]\], marmots \[[@pone.0238132.ref065]\], and woodchucks \[[@pone.0238132.ref066]\] to preserve bone mass deserve to be explored. In comparison with other hibernating mammals, bears have a large body size, near-to-normal body temperature during hibernation, and a drastic pre-hibernation fat storage \[[@pone.0238132.ref026],[@pone.0238132.ref027]\]; such peculiar differences may bring about bone preservation mechanisms that other hibernating mammals do not possess. McGee-Lawrence (2011) stated that although hibernating ground squirrels preserve macrostructural cortical bone geometry and strength, they undergo trabecular, and cortical bone loss on a microstructural scale during hibernation, which is different from hibernating bears bone condition \[[@pone.0238132.ref064]\]. Such differences might be due to species-specific osteogenic alterations, which have also been reported in other mammals. For instance, a transient physiological osteoporosis due to a rapid antler osteogenesis may occur in cervids, which is a distinct feature in comparison with other artiodactyls \[[@pone.0238132.ref067]\]. Hence, comprehensive and comparative studies on mammalian physiological bone preserving/ or osteoporotic mechanisms are needed to provide insights into mammalian bone biology.
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Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have investigated the effects of serum isolated from active and hibernating bears for osteoclastogenesis in vitro and observed that hibernating bear serum failed to promote osteoclastogenesis from PBMCs cultured with M-CSF and RANKL, although active bear serum promote that. In addition, the osteoclast culture from bears' PBMCs is significant. The manuscript is written in a clear and concise style. However, some concerns were raised.

Major issues:

The authors evaluated osteoclastogenesis only by areas of TRAP-positive cells in Figure 2 and 3. However, the reviewer feels that it is a little tenuous to determine the conclusion drawn from this data. Osteoclasts are multinucleated cells of differentiation and fusion of monocyte-macrophage precursors. The magnitude of bone resorption by osteoclasts is regulated by their number and the resorptive capacity of the individual cells. Therefore, measurements of the number of TRAP-positive multinucleated cells and the expression of osteoclastogenic markers such as β3 integrin, cathepsin K, TRAP, and calcitonin receptor could be more definitive evidence to support the data in Figure 2 and 3.

Minor issues:

1\. Did the authors separately use the PBMCs and serum from each bear? Please provide the detail sample numbers and replicates assigned for each experiment in the text of manuscript.

2\. The authors should provide cell number or concentration seeded for osteoclast culture.

3\. About figure 4, panels C-F, described in the text, are not found in the figure. The authors should check them.

Reviewer \#2: This is an interesting study that is consistent with osteoclastogenesis in peripheral blood mononuclear cells being influenced by serum factors in hibernating and active bears. This builds on some previous research with chicken osteoclastogenesis being affected by bear serum and the observation that bears do not suffer significant bone loss during hibernation. There are some troubling experimental design flaws in the paper that should be addressed before publication.

Introduction

Line 72: ground squirrels do not eat during hibernation and rarely urinate or defecate.

Line 80: it would be good to compare and contrast bears to what is known about bone loss in other hibernators such as ground squirrels. For example: McGee-Lawrence ME, Stoll DM, Mantila ER, Fahrner BK, Carey HV, Donahue SW. Thirteen-lined ground squirrels (Ictidomys tridecemlineatus) show microstructural bone loss during hibernation but preserve bone macrostructural geometry and strength. J Exp Biol 214: 1240--1247, 2011.

Line 82: change human to humans

Methods

Line 123: add "have" in front of "access" in both occurrences

Line 129: was blood collection done similarly for both hibernating and alert animals? Some anesthetics don't work as well on hibernating animals due to decreased circulation and metabolism

Line 131: if blood was collected in EDTA this would produce plasma. Was clotting initiated to form serum? Or was plasma actually used in the experiments.

Line 174: Change "Next day of" to "The day after"

For the experimental design (table 1 and lines 188-194)

I have a few concerns with the experimental design.

1\. While an n=3 for PBMCs is fairly low an n=1 for ADSC is unacceptably low. It also appears that individual PBMC cell preps were incubated with serum from individual animals. Were any experiments performed where a single cell prep was incubated with each of the different serum samples to ensure there were not differences between serum samples. Or a pooled serum sample could be used in common with all three cell preps. As the experiment is designed it is difficult to tell if any variation is due to the cell prep or the serum.

2\. The difference in growth between active (ABSM) and hibernating (HBSM) sera is interesting and suggests that ABSM contains an activator or HBSM contains an inhibitor of PBMC differentiation. A classical experimental method to test this is to either heat inactivate each serum or do a mixing experiment. For example if you heat inactivate ABSM and growth no longer occurs it could contain an activator, while if you heat inactivate HBSM and growth does occur then it contained an inhibitor. Similarly, if HBSM contains an inhibitor, adding it to ABSM could decrease growth. There are multiple ways these experiments may not work (heat stable factors, etc.) but they are fairly simple and broad experiments that would allow the authors to draw a more substantial conclusion about their results.

Results: The images are not of great quality, but if they meet the standards of the journal they should be sufficient. My major concern with the results are addressed above regarding the sample size, especially for ADSC, and the mixing and heat inactivation controls.

Discussion: A quick summary of the use of PBMCs in in vitro osteoclastogenesis should be added to the introduction. My first thought when reading the introduction is whether this model was physiologically relevant, i.e. how many osteoclasts arise from PBMCs vs. bone marrow. If this is the standard of the field it would be good to mention this up front.

The mixing and heat inactivation experiments are even more important to perform given the mention on line 296 that hibernating serum inhibits chicken OCs formation.

The authors come very close to concluding that HBSM might contain an OC inhibitor in lines 304-313. The experiments described above would allow them to test this hypothesis and make this conclusion directly.

The rest of the discussion speculates on possible factors that may be lacking in hibernating serum. I think the authors would be advised to first determine if an activator is lacking or an inhibitor is present before testing individual potential lead compounds.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Submitted filename: 2020 bear serum review.docx
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Click here for additional data file.
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Author response to Decision Letter 0

26 Jul 2020

Dear Reviewers,

I and co-authors would like to thank you for the constructive comments. The changes in the text were highlighted in yellow. The added references (reference number) in the text and reference list were highlighted in red. All the comments are responded as follows:

Regards,

Corresponding author

Reviewer \#1:

The authors have investigated the effects of serum isolated from active and hibernating bears for osteoclastogenesis in vitro and observed that hibernating bear serum failed to promote osteoclastogenesis from PBMCs cultured with M-CSF and RANKL, although active bear serum promote that. In addition, the osteoclast culture from bears' PBMCs is significant. The manuscript is written in a clear and concise style. However, some concerns were raised.

► Thank you very much for reviewing the present paper.

Major issues:

1\# The authors evaluated osteoclastogenesis only by areas of TRAP-positive cells in Figure 2 and 3. However, the reviewer feels that it is a little tenuous to determine the conclusion drawn from this data. Osteoclasts are multinucleated cells of differentiation and fusion of monocyte- macrophage precursors. The magnitude of bone resorption by osteoclasts is regulated by their number and the resorptive capacity of the individual cells. Therefore, measurements of the number of TRAP-positive multinucleated cells and the expression of osteoclastogenic markers such as β3 integrin, cathepsin K, TRAP, and calcitonin receptor could be more definitive evidence to support the data in Figure 2 and 3.

► In the present study, we considered two important (globally accepted) osteoclast features: multinucleated cell formation, and TRAP stainability. we asserted that the use of active phase serum (ABSM) leads to formation of multinucleated cells, while hibernation phase serum (HBSM) fails to form multinucleated cells, Line 54-57, 227-230, 284-286, i.e. presence of multinucleated cells with ABSM, and absence of multinucleated cells with HBSM. After TRAP stain, in order to make a quantitative comparison, the rate of stain absorption was compared between ABSM and HBSM cultured cells.

Figure 2 shows the presence and absence of multinucleated cells (morphology). Figure 3 shows the functionality of cells by TRAP stain. Although TRAP stain is not the only criterion to show functionality, TRAP stain is a critical parameter which indicates that cells are active, and have the potential for resorption (Sources: <https://doi.org/10.1007/BF02411252;> <https://doi.org/10.1007/BF01623458;> <https://doi.org/10.1080/08916930701694667>).

In agreement with your statement, specific makers such as cathepsin K, TRAP, etc. can reveal the pathways which ABSM is effective on osteoclastogensis. This is a very important part of our future study regarding evaluation of underlying mechanisms which are involved in "lack of osteoclastogenesis with HBSM". These have been added to the revised manuscript within Discussion, Line 351, 352. We will definitely consider your comments for our subsequent studies to explore the osteoclastogenesis mechanisms in bears' PBMCs by evaluation of bears' specific mRNA. However, the scope of the present work is to compare the effect of HBSM and ABSM on bears PBMCs. In addition we evaluated the serum effects on adipose derived stem cell response to clarify the difference in cell response (if any) to HBSM and ABSM.

Minor issues:

1\. Did the authors separately use the PBMCs and serum from each bear? Please provide the detail sample numbers and replicates assigned for each experiment in the text of manuscript.

► Yes, separately, and with replicates. Corrections have been made in Line 50-52, 153, 158, 191-194, 200, 201, Caption of Fig. 4.

Each cell (A, B, and C) were separately tested. Each cell was separately tested with each of 4 types of ABSM and HSBM. For example:

PBMCs of Bear A was cultured with ABSM of Bear D

PBMCs of Bear A was cultured with ABSM of Bear E

PBMCs of Bear A was cultured with ABSM of Bear F

PBMCs of Bear A was cultured with ABSM of Bear G

PBMCs of Bear A was cultured with HBSM of Bear C

PBMCs of Bear A was cultured with HBSM of Bear D

PBMCs of Bear A was cultured with HBSM of Bear H

PBMCs of Bear A was cultured with HBSM of Bear I

Similar procedure were used for PBMCs of Bears B and C.

2\. The authors should provide cell number or concentration seeded for osteoclast culture.

► Done. Line 172, 178, 179, 196, 197.

3\. About figure 4, panels C-F, described in the text, are not found in the figure. The authors should check them.

► Corrected. Line 242-246.

Reviewer \#2:

This is an interesting study that is consistent with osteoclastogenesis in peripheral blood mononuclear cells being influenced by serum factors in hibernating and active bears. This builds on some previous research with chicken osteoclastogenesis being affected by bear serum and the observation that bears do not suffer significant bone loss during hibernation. There are some troubling experimental design flaws in the paper that should be addressed before publication.

► Thank you very much for reviewing the present paper.

Introduction

1\# Line 72: ground squirrels do not eat during hibernation and rarely urinate or defecate.

► Yes, Good point. This paragraph is about the bears features. The statements about ground squirrels come in Discussion, Line 358-371.

One more thing is that, according to McGee-Lawrence et al., (2011) <https://doi.org/10.1242/jeb053520>, Page 1245:

"..other hibernators, such as ground squirrels, interrupt torpor bouts with periodic arousals to euthermia, during which they excrete calcium-containing waste. This provides a potential avenue for calcium and other products of bone catabolism to be excreted from the body, as occurs during other disuse situations such as human bedrest." This statement contradicts the physiologic response of hibernating bears.

2\# Line 80: it would be good to compare and contrast bears to what is known about bone loss in other hibernators such as ground squirrels. For example: McGee-Lawrence ME, Stoll DM, Mantila ER, Fahrner BK, Carey HV, Donahue SW. Thirteen-lined ground squirrels (Ictidomys tridecemlineatus) show microstructural bone loss during hibernation but preserve bone macrostructural geometry and strength. J Exp Biol 214: 1240--1247, 2011.

► The statements about ground squirrels come in Discussion, and also a comparison between species is mentioned therein, Line 358-371.

3\# Line 82: change human to humans

►Done. Line 83.

Methods

4\# Line 123: add "have" in front of "access" in both occurrences

► Done. Line 124.

5\# Line 129: was blood collection done similarly for both hibernating and alert animals? Some anesthetics don't work as well on hibernating animals due to decreased circulation and metabolism.

► Yes, it was similar for both. Induction of anesthesia to hibernating bears takes slightly longer time than active phase bears. Our protocol has been already established for captive Japanese black bears and is consistent with the protocol of anesthesia for black bears stated in the scientific literature. For example, (Source: Zoo Animal and Wildlife Immobilization and Anesthesia, 2nd edition, Editors: West, G., Heard, D., Caulkett, N. (2014) Blackwell, Page 605, Under topic "American Black Bears") states that "Medetomidine-zolazepam-tiletamine will induce a rapid onset of immobilization; it can be delivered in a small volume and it is readily reversible...".

Also, a similar method has been reported for anesthesia of hibernating bears, Source: Evans et al., 2012, Capture, anesthesia, and disturbance of free-ranging brown bears (Ursus arctos) during hibernation, <https://doi.org/10.1371/journal.pone.0040520>

6\# Line 131: if blood was collected in EDTA this would produce plasma. Was clotting initiated to form serum? Or was plasma actually used in the experiments.

►The sentence reads: "Blood was collected from the jugular vein into plain tubes and EDTA containing tubes for serum collection and peripheral blood mononuclear cells (PBMCs) isolation, respectively." This means in order to collect serum (to enrich the medium) we used plain tubes. For PBMCs collection, we used EDTA tubes. We used SERUM in the medium. Line 133.

7\# Line 174: Change "Next day of" to "The day after" For the experimental design (table 1 and lines 188-194)

►Done. Line 177.

I have a few concerns with the experimental design.

8\# 1. While an n=3 for PBMCs is fairly low an n=1 for ADSC is unacceptably low. It also appears that individual PBMC cell preps were incubated with serum from individual animals. Were any experiments performed where a single cell prep was incubated with each of the different serum samples to ensure there were not differences between serum samples. Or a pooled serum sample could be used in common with all three cell preps. As the experiment is designed it is difficult to tell if any variation is due

to the cell prep or the serum.

► The aim of the present study was to check the efficacy of the bears serum to promote osteoclasts formation in a comparative manner; hibernation phase serum Vs active phase serum. To do this, hibernating phase serum from four individuals (HBSM: C, D, H, I), and active phase serum from four individuals (ABSM: D, E, F, G) were assessed separately. These were conducted for PBMCs from three individuals (A, B, C) separately.

For example:

PBMCs of Bear A was cultured with ABSM of Bear D

PBMCs of Bear A was cultured with ABSM of Bear E

PBMCs of Bear A was cultured with ABSM of Bear F

PBMCs of Bear A was cultured with ABSM of Bear G

PBMCs of Bear A was cultured with HBSM of Bear C

PBMCs of Bear A was cultured with HBSM of Bear D

PBMCs of Bear A was cultured with HBSM of Bear H

PBMCs of Bear A was cultured with HBSM of Bear I

Similar procedure were used for PBMCs of Bears B and C.

Moreover, to check the influence of HBSM and ABSM on another cell lineage culture, we used stem cells driven from adipose tissue (ADSCs). Accordingly, ADSCs were cultured separately with four types of HBSM, and separately with four types of ABSM. This procedure were carried out twice; first passage and second passage. We did the second passage in order to check the influence of a previous culture (first passage) of the proliferation rate of ADSCs. Interestingly, both passages of 4 HBSM and 4 ABSM (which were separately tested) showed very harmonious results. This experiment shows 16 replications of tests.

One more thing; in order to answer the reviewer's concern regarding the number of ADSCs (only from one bear), we carried out one more test, but on a limited number of HBSM and ABSM due to limited volume of our serum stock. ADSCs of another bear was cultured for the first passage with one HBSM (D) and one ABSM (E), and then, for the second passage ADSCs were cultured with two HBSM (D, H) and two ABSM (E, F). Interestingly the results were in agreement with the ONE BEAR ADSCs stated in the main manuscript as follows below:

With regards to the use of bear serum for cell culture, our study has examined a passable number of tests on serum (with total 8 types) and cells (three types of PBMCs as the main subject). This is comparable with the sample size in previous studies regarding the effect of bears' serum for cell culture, as shown in the following box:

Rigano et al., 2016 (<https://doi.org/10.1007/s00360-016-1050-9>), page 8, 10: Four adult bears' cells were cultured with serum of only two bears.

Jansen et al., 2016 (<https://doi.org/10.1186/s12983-016-0173-x>) Page 6, 13: Cells and serum were collected from four bears.

Chanon et al., 2018 (<https://doi.org/10.1038/s41598-018-23891-5>), Page 2 , 3: Bears serum from two groups containing four mixtures of serum was used for culture of two groups of human muscle cells.

Overstreet et al., 2004 (<https://doi.org/10.1290/1543-706X>(2004)40\<4:IOOADA\>2.0.CO;2), Page 4: Serum from seven active bears and one hibernating bear was used for humans' osteoblast culture (not mentioned the number of subjects).

Due to the limitations of experiments on wild animals, and our institutional regulations regarding the demarcated collection of samples from hibernating animals (which do not have access to food , and are exposed to very low ambient temperature), we designed our tests to the maximum possible variations.

9\# 2. The difference in growth between active (ABSM) and hibernating (HBSM) sera is interesting and suggests that ABSM contains an activator or HBSM contains an inhibitor of PBMC differentiation. A classical experimental method to test this is to either heat inactivate each serum or do a mixing experiment. For example if you heat inactivate ABSM and growth no longer occurs it could contain an activator, while if you heat inactivate HBSM and growth does occur then it contained an inhibitor. Similarly, if HBSM contains an inhibitor, adding it to ABSM could decrease growth. There are multiple ways these experiments may not work (heat stable factors, etc.) but they are fairly simple and broad experiments that would allow the authors to draw a more substantial conclusion about their results.

► In order to check the effect of heat inactivation, we checked the recent scientific literature, and found that Rigano et al., 2016 (<https://doi.org/10.1007/s00360-016-1050-9>) employed bear serum heat inactivation in their experiment for cell culture. According to that study, page 10: serum was heated for 30 min at 65°C and filtered. Therefore, in order to compare our results with the stated work, we followed the same procedure. When we heated (at 65°C for 30 min) 2 ml of 2 active bears serum and 2 ml of 2 hibernating bears serum, the serum completely coagulated, and became solid; a form which could not be used into medium. We repeated this test, one more time, for four more bear serums, and again found the same results. Afterwards, we checked scientific literature regarding the reason for serum coagulation. We found out that heating of serum to temperatures higher than 58-60°C causes coagulation. This form is not reversible; similar to eggs when eggs are boiled. The coagulated serum cannot be used in the medium. The following figures show the coagulated bear serum when heated at 65°C for 30 min:

The scientific literature confirms our observation in that the 65°C heat causes serum coagulation, in the following box:

� Ballou GA, Boyer PD, Luck JM, Lum FG. The heat coagulation of human serum albumin. Journal of Biological Chemistry. 1944 May 1;153(2):589-605. <https://pdfs.semanticscholar.org/3532/15f5895f2b7d6d5dcfdb5459b71d0221e53d.pdf>

� Page 593, Fig. 2. shows the cloud formation in serum samples subjected to temperatures higher than 60° C.

� Page 594, Table.1. shows the relation between time, temperature and coagulation.

� And many other similar statements in the article.

� Tekman S, Öner N. Alterations in protein fractions of heated blood serum. Nature. 1966 Oct 22;212(5060):396-. <https://www.nature.com/articles/212396a0>

� Page 396, The samples which were heated to 50° C and 55° C showed an electrophoretic pattern similar to that of unheated blood serum. However, the sample which was heated to 60° C showed initial alteration in the globulin areas (alpha and beta-globulin fractions came together to form a single fraction). The sample which was heated to 65° C showed decreased albumin mobility and no fractionation of the globulin fractions. And samples that were heated to 65° C had a trace of opalescence.

Also other sources with a similar concept:

� Donnelly EB, Delaney RA, Kennedy R. Studies on Slaughter Animal Blood Plasma: II. Heat Lability of Blood Plasma Proteins. Irish Journal of Food Science and Technology. 1978 Jan 1:39-44. <https://www.jstor.org/stable/25557950?seq=1#metadata_info_tab_contents>

� Glass GB. The thermal coagulation point of blood serum: III. Correlation with serum proteins, sedimentation rate and Weltmann reaction. The American journal of medicine. 1950 Jun 1;8(6):759-66. <https://www.amjmed.com/article/0002-9343>(50)90101-X/fulltext

Therefore, the method of Rigano et al., 2016 was not reproducible, and it was practically erroneous.

Basically, heat inactivation is a method to inhibit complement reactions, and remove fibrin. To inactivate serum, it should be heated 55-56° C for about 30 min, Source: Simon J, Müller J, Ghazaryan A, Morsbach S, Mailänder V, Landfester K. Protein denaturation caused by heat inactivation detrimentally affects biomolecular corona formation and cellular uptake. Nanoscale. 2018;10(45):21096-105. <https://pubs.rsc.org/lv/content/articlehtml/2018/nr/c8nr07424k>

Finally, when we followed method "56° C for 30 min", we found that the serum samples remained normal (retained their fluidity), and were fine to be used in the culture medium. Thereafter, the heat inactivated serums were filtered with 0.22 um filter, and added into medium.

The heat inactivated ABSM and HBSM were used for PBMCs of Bear A. During the 11 days of culture, cells were poorly adhering to the dish and almost majority of the cells were dead, and no multinucleated osteoclasts were formed. We repeated the test with PBMCs of bear C, and added two control positive (two separate intact ABSM which were unheated). Similar to the previous test (= bear A), PBMCs of bear C which were cultured with heat inactivated HBSM were almost all dead (detached/ floating), and PBMCs which were cultured with heat inactivated ABSM contained floating cells, and there was very low cell density, though relatively more than inactivated HBSM. Positive control (two separate intact ABSM which were unheated) showed full differentiation and formed multi-nucleated/ TRAP positive osteoclasts.

We conducted one more test, to check the effect of heat inactivated serum on ADSCs. To do this, we used the same heat inactivated ABSM and HBSM to culture ADSCs. In both first and second passage, ADSCs proliferated very well; quite similar to those of intact (unheated) ABSM and HBSM. The following figures show the results:

The difference in results between the effect of heat inactivated serum on PBMCs and ADSCs may be due to the deleted components which are essential for PBMCs culture, but not for ADSCs. A previous study has shown the different effects of serum heat inactivation on some sort of cells, Source: Giard DJ. Routine heat inactivation of serum reduces its capacity to promote cell attachment. In vitro cellular & developmental biology. 1987 Oct 1;23(10):691-7. <https://link.springer.com/article/10.1007/BF02620982>. Giard (1987) stated that calf serum heat inactivation had negative effects on SV-BHK and CV-1 cells, but not much on fibroblasts.

Based on the current results, it is not feasible to conclude that the difference in "heat labile" serum factors in HBSM Vs ABSM can promote or demote PBMCs differentiation. More importantly, heat inactivated serum (both ABSM and HBSM) indicated normal and almost equal ADSCs proliferation. Thus, since it is difficult to prove or disprove the effect of heat labile serum ingredients in ABSM or HBSM for PBMCs differentiation, and that there are numerous components that are affect by heating serum (e.g. proteins, peptides, vitamins, antioxidants, microRNAs) which does not specify heat-targeted components, we preferred not to state these results in the manuscript. We just briefly stated the heat inactivation results in discussion Line 340-345. Further work is required to delve into the serum ingredients which encourage/discourage bears PBMCs response.

10\# Results: The images are not of great quality, but if they meet the standards of the journal they should be sufficient. My major concern with the results are addressed above regarding the sample size, especially for ADSC, and the mixing and heat inactivation controls.

►We uploaded the figures with maximum possible size and quality. During conversion of file to PDF, the quality may have decreased.

11\# Discussion: A quick summary of the use of PBMCs in in vitro osteoclastogenesis should be added to the introduction. My first thought when reading the introduction is whether this model was physiologically relevant, i.e. how many osteoclasts arise from PBMCs vs. bone marrow. If this is the standard of the field it would be good to mention this up front.

► Done. Line 94, 95. In addition, the use of PBMCs for osteoclastogenesis has been mentioned in the first paragraph of discussion.

12\# The mixing and heat inactivation experiments are even more important to perform given the mention on line 296 that hibernating serum inhibits chicken OCs formation. The authors come very close to concluding that HBSM might contain an OC inhibitor in lines 304-313. The experiments described above would allow them to test this hypothesis and make this conclusion directly. The rest of the discussion speculates on possible factors that may be lacking in hibernating serum. I think the authors would be advised to first determine if an activator is lacking or an inhibitor is present before testing individual potential lead compounds.

►The effect of heat inactivation was mentioned above.

The "mixing experiment", however, is very demanding since it requires multiple sets of pair test of active and hibernating individual serums. As mentioned before, there are four types of active phase serum samples (D,E,F,G) and four types of hibernating phase serum samples (C,D,H,I). To test "mixing effect" one should tests multiple combinations (permutations), e.g. D&C, D&D, D&H, D&I, E&C, E&D, E&H, E&I, and so on. As we mentioned before we have had a demarcated amount of sample for the current experiment. This must be noted that the "individual differences" also matter for such cases. That is, the activating factors of an active bear might be weaker or stronger than inhibiting factors of a hibernating bear, or vice versa. This means that the sample size for assessment of "mixing effect" should comprise the comparison several individuals and consider different ages, body weights, and sexes. However, in order to provide a very basic response to the reviewer, we examined a mixture of one active (10%) and one hibernating bear serum (10%). Moreover, a positive control (one unheated 10% ABSM of the same type used for mixing experiment) and a negative control (one unheated 10% HBSM of the same type used for mixing experiment) were checked. We found that:

\- Positive control: PBMCs completely differentiated to multi-nucleated osteoclasts, and was TRAP positive.

\- Negative control: PBMCs failed to differentiate to multi-nucleated osteoclasts, and were TRAP negative.

\- Mixing experiment (mixture of the abovementioned positive serum \[active phase\] and negative serum \[hibernation phase\]): PBMCs were mostly differentiated to multi-nucleated osteoclasts and were TRAP positive. However, there were some multi-nucleated cells which were TRAP negative. These may indicate a co-dominance for both serum types.

We selected this method to compare 10% active phase serum versus 10% hibernating phase serum. However, this made the total serum ratio of our "mixing experiment" to 20% which is different from the 10% serum content in the main text! which is another setback for interpretation of results of mixing experiment. In our test, we only checked the mixture of one active and one hibernation phase serum. With respect to mixing effects, further studies will be required to check not only the differences in individual serum effects with more sample size, but also to check different ratios of the serum implemented in the culture medium. Since our mixing experiment was restricted in terms of sample size, and the results need further evaluation, we preferred not to mention this experiment in the text of the manuscript.

###### 

Submitted filename: Response to Reviewers.pdf

###### 

Click here for additional data file.

10.1371/journal.pone.0238132.r003

Decision Letter 1

Shi

Xing-Ming

Academic Editor

© 2020 Xing-Ming Shi

2020

Xing-Ming Shi

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

11 Aug 2020

Hibernating bear serum hinders osteoclastogenesis in-vitro
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